REMARKS

In response to the Communication dated January 9, 2002, applicants have amended the application to include "SEQ ID NO." identifiers as required by the Examiner. Applicants have also amended the Sequence Listing to include sequences (SEQ ID NOS.: 6 to 10) which appeared in the application as filed, but which were not included in the original Sequence Listing.

Enclosed also is a diskette containing the Sequence Listing in computer-readable format, along with a copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, as requested in the Communication.

STATEMENT

In accordance with 37 CFR §1.821(g) relating to submissions containing Sequence Listings after the time of filing of the application, the undersigned hereby certifies that:

(A) the contents of the computer-readable copy of the Sequence Listing submitted herewith and the paper copy of the Sequence Listing are the same;

(B) all of the sequences are reflected in the application as filed; and

(C) the present submission contains no new matter.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "Version with Markings to Show Changes Made."

Respectfully submitted,

Patrick J. Kelly, Ph.D.
Registration No. 34,638

SYNNESTVEDT & LECHNER LLP
Suite 2600 Aramark Tower
1101 Market Street
Philadelphia, PA 19107
(215) 923-4466

M:\LWhite\RPR\23461-A USA\sequence listing amd.wpd

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Page 56, lines 26 and 27, have been amended as follows:

PCR reactions were performed using PCR primers

5'hasm - 5'-tccaccatggcgctggtgcgcgcactc-3' (SEQ ID NO.: 6) and

Page 57, lines 1 to 7, have been amended as follows:

fushasm3' - 3'-ctggatatcgtaattgtgctttatataaagctg-5' (SEQ ID NO.: 7) and the pCR2.1 construct for each full length clone as template. PCR conditions using 475pg of pCR2.1 clone 7a or 500 pg of pCR2.1 clone 14b were as follows: the reaction mixtures were heated to 95°C for 10 minutes, then thermocycled 30 times with a denaturing step of 95°C for 30 seconds, an annealing step of 52°C for 30 seconds, and then an extension step of 72°C for 1.5 minutes. Following these 30 cycles, the reactions were incubated at 72°C for 7 minutes, and stored at 4°C.

Page 57, lines 20 to 25, have been amended as follows:

hasm313mut + hasm3'mut:

5' gctccaccatgatatggacaggggatag 3' (SEQ ID NO.: 8)

5' gccactgtgctggatatcgtaattaac 3' (SEQ ID NO.: 9)

hasm396mut + hasm3'mut:

5' gctccaccatgacaaccaccatccagagtc 3' (SEQ ID NO.: 10)

5' gccactgtgctggatatcgtaattaac 3' (SEQ ID NO.: 9)

The paragraph that appears on page 60, lines 7 to 16, has been amended as follows:

In order to determine if the NFIF protein was associated with pathologies including atherosclerosis that involve inflammation and to identify tissues that may be treated using the methods of the present invention, an immunocytochemical study was performed using a rabbit monoclonal antibody designated 99-06 directed against a peptide antigen (SKGANASNPGPFGDV) (SEQ ID NO.: 5) derived from residues 65 to 79 of the NFIF

protein. The peptide was synthesized at the 0.25 mmole scale using a solid phase methodology FMOC (9-fluorenylmethyloxycarbonyl) protection scheme in conjunction with the HOBT/HBTU activation chemistry (Fields et al., *Peptide Research*, 4:95-101 (1991)). An Applied Biosystems 433 Peptide Synthesizer running Applied Biosystems Fast-Moc coupling cycle was used for the synthesis of the peptide.

The Sequence Listing which appears on pages 65 to 70 has been deleted in its entirety, and the enclosed Sequence Listing, as pages 65 to 71, has been inserted therefor.

The pages which contain the claims and Abstract have been renumbered as new pages 72 to 77.